Skip to content

A two-center prospective observational study of treatment continuity with PICC versus subcutaneous route in hospitalized cancer patients receiving palliative care

A two-center prospective observational cohort study comparing 14-day treatment continuity of PICC versus subcutaneous route in hospitalized cancer patients receiving palliative care - PICC-SC study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000061237
Enrollment
900
Registered
2026-04-13
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

None listed

Sponsors

Osaka Rosai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Cancer patients aged 18 years or older receiving palliative care. Patients judged clinically to have difficulty in securing peripheral venous access, or expected to have such difficulty in the near future, and requiring continuation of injectable treatment. Patients for whom either PICC or the subcutaneous route (SC) is considered a clinically appropriate option, and whose attending physician selected one of these routes (initiation of SC or PICC order/insertion). The presence or absence of an implanted port is not restricted; however, only patients in whom the attending physician judged that the port alone was insufficient to continue the main injectable treatment of interest, or that an additional route was clinically necessary, and who were newly selected for PICC or SC, are eligible.

Exclusion criteria

Exclusion criteria: Patients in whom stable injectable treatment can be continued via peripheral venous access and for whom PICC or SC is not clinically considered. Patients with a PICC already inserted by another department or service and already being continuously used as the main route for injectable treatment at the time of study allocation. Patients with an absolute contraindication to PICC insertion, such as obvious infection at the planned insertion site, known deep vein thrombosis of the intended upper extremity or severe venous obstruction, uncontrolled major bleeding risk, or explicit patient refusal. Patients who expressed refusal to participate in the study through the opt-out process.

Design outcomes

Primary

MeasureTime frame
Treatment continuity over 14 days. This is defined as maintenance of the selected main route from Day 0 (the day SC or PICC started as the main route) through Day 14 without access-related failure.

Countries

Japan

Contacts

Public ContactNoriyuki Kawabata

Osaka Rosai Hospital Department of Palliative Care

off.kawabata@gmail.com072-252-3561

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026